This is the first analysis of real-world experience for intraoperative molecular imaging (IMI) with CYTALUX following the phase 3 ELUCIDATE trial for cancer in the lung. The clinical outcome demonstrated an improvement in lung nodule localization, occult lesion identification and resection margin assessment. a single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed.